Interesting Times – How to spend £14bn in a weekend
Finding a title for a blog after an interesting meeting is usually straight forward. One tends to pop out during or after the occasion, but find myself stumped. Several possible titles present themselves after a talk about the Financial Services Compensation Scheme like: Thank your lucky stars! Here comes the cavalry or the old Chinese curse, May you live in interesting times!
Last 18 months have certainly been interesting with £21 billion paid out in compensation. Surrounded by pictures of the great & good in Lloyds Old Library, Loretta Minghella FSCS Chief Executive took us through her term. FSCS exists as a safety net to pay compensation to customers of firms regulated by the FSA and was formed December 2001 as the result of mergers of several compensation schemes under the Financial Services & Markets Act 2000. Limits are: http://www.fscs.org.uk//consumer/what_we_cover/Eligibility_Rules/compensation_limits/ but compensation kicks in where the regulated firm is unable or likely to be unable to pay claims.
Being independent of the financial services industry and not a consumer group either, it is financed by a compulsory levy. The funding structure is complicated but when one level of compensation money runs out, other broader ones kick in giving it a capability of raising up to £4 billion in one year www://www.fscs.org.uk/industry/funding/ Working on a pay as you go basis with no pre-funding, the FSCS took out Government loans when it had to step in when four banks failed in two weeks in 2008. Number of phone calls to FSCS when Lehman went down – who did not have a retail branch network – was 10x the number received when it was all happening to Northern Rock.
When the question is “Where do you borrow £14 billion?” and it’s a weekend, the answer is Treasury/Bank of England. With Bradford & Bingley, a deal was arranged over the weekend, £14 billion transferred Monday morning with the main casualty being someone’s wedding anniversary. Interest is 30 basis points (0.3 per cent) over LIBOR the interbank/money market rate and when money comes in from recoveries and the sale of failed company assets, this is used to reduce the principal.
Part of the reason for the famous queues at Northern Rock was the lack of awareness of the FSCS. Only 21 per cent of the population were aware of it in a recent survey. Current work in progress of failed institutions includes: 27 General Insurance companies, 2 Life Insurance companies & 5 banks. Unsurprisingly, this includes paying compensation to customers of Payment Protection Insurance companies http://www.georgeemsden.co.uk/2009/02/reasons-to-be-cheerful/ and my other bête noire Structured Products http://www.georgeemsden.co.uk/2009/10/pica-pica-pica/
Development includes new IT systems for all banks to produce a so called “single customer view” so if one fails, the extent of the liabilities can be known instantly. Trawling through thousands of complicated data sets would take forever and the loss of confidence would be terrible. The on-line system for Icesave compensation for example, was set up in three weeks and between the September and Christmas concerned, 190,000 Icesave customers got their money this way in a process lasting a few minutes. A paper-based system would have been a joke by comparison.
While the scope of the FSCS protection is much broader than any other EU state, it does have limits. Compensation is just for financial loss and only the Financial Ombudsman Service http://www.financial-ombudsman.org.uk/ can make awards for distress and inconvenience. Some EU states have compensation schemes for deposits, other for investments, others for insurance &c. but the UK system is the broadest. A new EU Directive will make it necessary for all states to have depositor protection and will eventually cover all the other areas too. This might also stop the financial regulatory equivalent of asylum seekers or people from a poorly protected financial environment piggy-backing onto our more comprehensive one.
www.3cscommunity.org meeting at Simmons & Simmons is another vintage occasion. First speaker who has been there and done that, having set up and sold two companies, warns of the dangers of floating your company. Ordinary shares are not always popular with brokers as they might be unable to do some smoke and mirrors. The story tells of A warrants, B warrants, brokers’ warrants and Convertible Preference shares all which have advantages and disadvantages depending on whether the share price goes up/down and by how much. Moral appears to be “don’t always trust your broker!” which is difficult if he is handling the sale of your business. Other morals are keep the nominal value of your shares small e.g. .001p rather than say, £1 and keep control of the Board. Cliques can form and you might find yourself ejected from your own business.
Fascinating but scary presentation from THOR Photomedicine who specialise in LLLT or Low-level Laser Treatment. Can remember a TV programme years ago when someone said that “Lasers were a solution looking for a problem!” LLLT used in treatment of neck-pain for example, avoids the use of NSAIDs or Non-steroidal anti-inflammatory drugs which seem to have some horrifying effects. They are the 15th largest cause of death in the USA, can inhibit healing for other conditions not to mention reducing erectile function. Cure worse than the disease? Other areas of treatment are cancer sufferers who have had chemo - apparently they lose the lining of their mouth & intestines making eating painful and shingles sufferers whose skin can become ultra sensitive. Results appear to be confirmed by several cross-over placebo studies i.e. the real treatment and a dummy treatment are swapped halfway through the trial. 200 papers have been published about LLLT i.e. more than some prescription medicines including the ones given for AIDS. Presenter doesn’t know how much funding is required yet but there are plenty of people at 3Cs to help here. The potential is in the future delivery of the LLLT treatment e.g. knowing the right wavelength to have the best healing effect.
The idea is almost ancient being first mentioned in 1967 by an iron curtain country which did not have the resources to develop it. In other words, inventing a new medicine doesn’t seem to be a way to get rich quick, as the development time from discovery to mainstream is 40 years!